Keynote Day 3 -

Keynote Day 3

Breaking Data Silos to Realize True Digital Transformation in Biopharma R&D

CDOs across industries are challenged with maximizing value from data spanning disparate sources, formats, and regulatory jurisdictions. Nowhere is this truer than in the pharmaceutical and medical industries where data is highly sensitive, complex, regulated, and siloed. The industry has viewed digital transformation as a massive opportunity to counter productivity headwinds and other operational hurdles. While AI offers great promise towards these goals, true insights at scale require access to huge amounts of data in consistent and accessible forms and creating powerful algorithms to analyze the data. And even then, data scientists need to have well defined questions in order to create meaningful insights.

Companies that are succeeding with true data transformation in biopharma can show us:

How to break down data silos organizationally, culturally, and technically
How to curate and harmonize data from hundreds of disparate sources
Manage the regulatory, privacy and usage challenges that pervade many sensitive healthcare data sources
How to ensure the right questions get asked to drive real value from the answers
How to use artificial intelligence and machine learning (AI/ML) for analytics, such as those yielding insights into diseases, patient journeys, and potentially treatments for unmet medical need
How to build innovation networks and safely share data amongst innovation partners – further accelerating and enhancing the impact of digital innovations

Join Sarah Lyons, the award-winning leader of Privacy Analytics, one of the world’s leading data transformation companies, as she and Gabriel Eichler – VP of Data responsible for Novartis’s transformative data42 strategy – explore the insights and experiences we’ve learned so far.

Insights include:

The challenges facing R&D productivity facing the industry as a whole
What a bold vision Novartis has brought to Data & Reimaging Medicine
The complexity of reapplying data collected in clinical trials, and the opportunities to drive new insights by enhancing their accessibility
How to govern data to enable true democratization while simultaneously protecting the organization and the patients it serves
In a world of massive uncertainty, what high-performing data leaders and organizations have learned about data transformation.